Clinical Read2026-06-09

EBGLYSS (lebrikizumab-lbkz) - (ADjoin)

Eli Lilly and CompanyLLY
Indication
Children >12 yo and up with at least 88 pounds (40 kg) Moderate-to-severe atopic dermatitis
Stage
phase6
Event
Approved